This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SNDX - Syndax targets $10B market as Revuforj gains NPM1 approval and Q3 revenue rises 21%

SNDX - Syndax targets $10B market as Revuforj gains NPM1 approval and Q3 revenue rises 21%

November, 03 2025 09:07 PM Syndax Pharmaceuticals Inc.

2025-11-03 21:07:37 ET

More on Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript
Syndax Expands Revuforj Approval, Buy
Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript
Syndax Pharmaceuticals GAAP EPS of -$0.70 beats by $0.04, revenue of $45.9M misses by $2.07M
Syndax Pharmaceuticals Q3 2025 Earnings Preview

For further details see:

Syndax targets $10B market as Revuforj gains NPM1 approval and Q3 revenue rises 21%

Stock Information

Company Name:	Syndax Pharmaceuticals Inc.
Stock Symbol:	SNDX
Market:	NASDAQ
Website:	syndax.com

Get SNDX Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.